Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.
Neuren Pharmaceuticals announced that the FDA has granted Fast Track designation for NNZ-2591 for treating Phelan-McDermid syndrome (PMS), a condition with no current FDA-approved treatments. This designation aims to expedite the drug’s development and review process, highlighting the urgent unmet medical need for PMS therapies. The company is conducting a Phase 3 clinical trial, marking the first of its kind for PMS, which could significantly impact the community affected by this syndrome. Fast Track status has also been granted for NNZ-2591 in Angelman syndrome, enhancing Neuren’s positioning in the neurodevelopmental disorder treatment market.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$21.20 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is focused on developing drug therapies for serious neurological disorders that emerge in early childhood, which have limited or no approved treatment options. The company has developed DAYBUE™ (trofinetide), approved for Rett syndrome, and is working on NNZ-2591 for various neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.
YTD Price Performance: 65.20%
Average Trading Volume: 548,381
Technical Sentiment Signal: Buy
Current Market Cap: A$2.61B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.